Royalty Pharma plc
RPRX
$39.67
$0.140.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 855.12% | -87.34% | 14.47% | -61.72% | 433.30% |
| Total Depreciation and Amortization | -7.40% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 15.70% | 0.45% | -0.47% | -0.79% | 17.31% |
| Total Other Non-Cash Items | 5.48% | -8.79% | -37.61% | 51.51% | -268.63% |
| Change in Net Operating Assets | 7.12% | 1.43% | -7.69% | 7.26% | 7.43% |
| Cash from Operations | 93.03% | -38.94% | -19.72% | 5.53% | 6.90% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 99.70% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -302.91% | -147.19% | 199.67% | 57.61% | -33.53% |
| Cash from Investing | -207.17% | -161.91% | 199.67% | 57.61% | -33.53% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 49.76% | 58.86% | -1,247.31% | 45.79% | -21.31% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.22% | 2.22% | -1.82% | 0.43% | 0.93% |
| Other Financing Activities | -21.90% | 10.32% | -22.79% | 16.89% | 3.78% |
| Cash from Financing | 210.82% | 46.05% | -264.90% | 20.75% | -128.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 167.36% | -387.23% | 854.75% | 97.42% | -188.38% |